Truist Financial Corp cut its stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 28.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 34,327 shares of the medical research company’s stock after selling 13,595 shares during the period. Truist Financial Corp’s holdings in Natera were worth $1,906,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Assetmark Inc. raised its position in Natera by 31.5% during the 1st quarter. Assetmark Inc. now owns 3,427 shares of the medical research company’s stock worth $190,000 after buying an additional 821 shares during the last quarter. Essex Investment Management Co. LLC purchased a new position in shares of Natera during the 1st quarter worth approximately $1,310,000. Treasurer of the State of North Carolina raised its stake in shares of Natera by 0.7% during the 1st quarter. Treasurer of the State of North Carolina now owns 42,699 shares of the medical research company’s stock worth $2,371,000 after buying an additional 300 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Natera by 3.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 197,836 shares of the medical research company’s stock worth $10,984,000 after buying an additional 6,572 shares in the last quarter. Finally, EFG Asset Management Americas Corp. raised its stake in shares of Natera by 12.9% during the 1st quarter. EFG Asset Management Americas Corp. now owns 6,775 shares of the medical research company’s stock worth $376,000 after buying an additional 772 shares in the last quarter. 92.18% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on NTRA shares. The Goldman Sachs Group cut their price target on shares of Natera from $70.00 to $60.00 and set a “buy” rating for the company in a report on Friday, July 21st. Credit Suisse Group reiterated an “outperform” rating and issued a $70.00 price target on shares of Natera in a report on Friday, August 4th. Morgan Stanley cut their price target on shares of Natera from $72.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, August 7th. UBS Group assumed coverage on Natera in a report on Friday, May 5th. They set a “buy” rating and a $76.00 price objective for the company. Finally, Robert W. Baird upped their target price on Natera from $65.00 to $66.00 in a report on Wednesday, May 10th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.22.
Read Our Latest Analysis on NTRA
Insider Buying and Selling
In related news, insider Jonathan Sheena sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $49.13, for a total transaction of $245,650.00. Following the sale, the insider now owns 514,746 shares in the company, valued at $25,289,470.98. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Natera news, CEO Steven Leonard Chapman sold 2,578 shares of Natera stock in a transaction on Friday, August 11th. The shares were sold at an average price of $55.00, for a total value of $141,790.00. Following the transaction, the chief executive officer now owns 214,988 shares in the company, valued at approximately $11,824,340. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 5,000 shares of Natera stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $49.13, for a total transaction of $245,650.00. Following the completion of the transaction, the insider now owns 514,746 shares in the company, valued at approximately $25,289,470.98. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,493 shares of company stock worth $1,401,628. 9.42% of the stock is owned by insiders.
Natera Stock Down 2.5 %
NTRA opened at $51.97 on Friday. The company has a quick ratio of 3.69, a current ratio of 3.85 and a debt-to-equity ratio of 0.47. The firm has a market cap of $5.96 billion, a P/E ratio of -10.78 and a beta of 1.18. Natera, Inc. has a 52 week low of $34.00 and a 52 week high of $59.75. The business’s fifty day simple moving average is $49.69 and its 200 day simple moving average is $50.60.
Natera (NASDAQ:NTRA – Get Free Report) last announced its earnings results on Thursday, August 3rd. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.12. Natera had a negative net margin of 54.97% and a negative return on equity of 88.47%. The firm had revenue of $261.40 million for the quarter, compared to analyst estimates of $241.67 million. During the same quarter last year, the business earned ($1.50) earnings per share. Natera’s revenue was up 31.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Natera, Inc. will post -4.03 EPS for the current fiscal year.
Natera Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Natera, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Natera wasn’t on the list.
While Natera currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Which stocks are major institutional investors including hedge funds and endowments buying in today’s market? Click the link below and we’ll send you MarketBeat’s list of thirteen stocks that institutional investors are buying up as quickly as they can.
Source: marketbeat.com
